Voyager Therapeutics stock tumbles after IND application delayed

Published 11/02/2025, 20:18
© Reuters.

Investing.com -- Shares of Voyager Therapeutics (NASDAQ:VYGR) plummeted 20% as the company announced a shift in its gene therapy program for amyotrophic lateral sclerosis (ALS), which will involve assessing alternate payloads. This adjustment is expected to push the company’s cash runway into mid-2027.

The biotechnology firm, which specializes in neurogenetic medicines, revealed that the siRNA payload component of its development candidate VY9323 did not meet the desired standards due to an off-target effect that narrowed the therapeutic window. As a result, the investigational new drug (IND) application for VY9323, previously slated for mid-2025, will be delayed as the company seeks an alternative payload.

Voyager’s CEO, Dr. Alfred W. Sandrock, Jr., expressed disappointment in the development candidate VY9323 not advancing but remained hopeful for identifying a new payload and continuing the program. He also highlighted the consistent performance of the company’s novel TRACER capsids across multiple programs, which he believes could transform gene therapy for central nervous system (CNS) diseases.

Despite the setback with VY9323, Voyager Therapeutics anticipates IND filings in 2025 for gene therapy candidates targeting GBA1 Parkinson’s and other GBA1-mediated diseases, as well as Friedreich’s ataxia, in partnership with Neurocrine (NASDAQ:NBIX) Biosciences. Additionally, an IND filing for VY1706 is expected in 2026.

The company’s decision to reassess the VY9323 program does not affect its other gene therapy programs. Further updates on the expected timing for the SOD1 ALS program will be provided when appropriate.

Voyager Therapeutics will be presenting additional data at the Oppenheimer 25th Annual Healthcare Life Sciences Conference, and the presentation will be available on the company’s website for at least 90 days following the event.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.